D. Western Therapeutics Institute (TYO:4576) has entered into a joint research agreement with Professor Hitoshi Kasai of Tohoku University to develop new formulations for treating eye diseases, according to a Monday filing on the Tokyo Stock Exchange.
The collaboration, which will be conducted through the Aoba Foundation For The Promotion of Engineering, focuses on addressing the unmet medical needs in retinal diseases like retinitis pigmentosa, diabetic retinopathy, and age-related macular degeneration, as well as conditions like cataracts that currently rely on surgery.
The joint research will explore the development of organic nanomaterials and nanodrugs to enhance drug efficacy and intraocular penetration.
The company said it aims to expand its pipeline and meet the growing demand for drug-based treatments.
Price (JPY): $108.00, Change: $+2.0, Percent Change: +1.89%
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。